[基金项目]

[](No.30325045);(No.30271648)Correspondenceto:PingREN.E-mail:[e-mail]1,2,1,3,2,3,3,2(1.,610041;2.,610041;3.,610041)[]:(pharmacokinetics,PK),(ferulicacid,FA)PK:21202219,,FAPK:,,;;;:PK,;PK;PKPK[];;;;[]R285.6[]A[]1672-1977(2006)-02-0147-05Pharmacokineticcharacteristicsofferulicacidinpatientswithdifferentsyndromesofdeficiencyofspleenqi,stagnationofliverqiandspleendeficiency,andexcessofstomachheatPingREN1,XiHUANG2,Shuang-QingLI1,Shu-YunXU3,Mei-HuaWAN2,Ya-XiongZHOU3,Yi-WuZHOU3,Wen-FuTANG2(1.DepartmentofGeneralMedicine,WestChinaHospital,SichuanUniversity,Chengdu,SichuanProvince610041,China;2.DepartmentofIntegratedChineseandWesternMedicine,WestChinaHospital,SichuanUniversity,Chengdu,SichuanProvince610041,China;3.DepartmentofEmergency,WestChinaHospital,SichuanUniversity,Chengdu,SichuanProvince610041,China)ABSTRACTObjective:ToinvestigatethenatureofsyndromeoftraditionalChinesemedicinebymeansofpharmacokinetic(PK)method.Methods:Twenty-onehealthyvolunteers,20patientswithsyndromeofstag-nationofliverqiandspleendeficiency,22patientswithsyndromeofdeficiencyofspleenqiand19patientswithsyndromeofexcessofstomachheatwereincludedandadministeredtotakeJiaweiXiaoyaosanRecipe(JWXYSR).TheserumPKparametersofferulicacid(FA)wereexaminedbyhighperformanceliquidchro-matography(HPLC)method.Results:Theabsorptionrateconstant()andtheeliminationrateconstant()werebothdecreasedwhiletheapparentfirst-orderabsorptionconstant(Ka)wasenhancedsignificantlyinthepatientswithsyndromeofdeficiencyofspleenqi;the,andKawereallreducedinthepatientswithsyndromeofstagnationofliverqiandspleendeficiency;theandKawereincreasedinthepatientswithsyndromeofexcessofstomachheat,ascomparedwiththecorrespondingPKparametersinthehealthyvol-unteers(P0.01).Conclusion:ThePKanalysisofFAinthepatientswithsyndromeofdeficiencyofspleen7412006342JournalofChineseIntegrativeMedicine,March2006,Vol.4,No.2qishowsthattheabsorptionrateisaccelerated,andboththedistributionandeliminationratesaresloweddown.Theabsorption,distributionandeliminationratesofAFareallsloweddowninthepatientswithsyn-dromeofstagnationofliver-qiandspleendeficiency,whiletheabsorptionandeliminationratesofAFarebothacceleratedinthepatientswithsyndromeofexcessofstomachheat.ThereareobviousdifferencesinthePKcharacteristicsamongthesethreesyndromes.KEYWORDSsyndromeofdeficiencyofspleenqi;syndromeofstagnationofliverqiandspleendeficiency;syndromeofexcessofstomachheat;ferulicacid;pharmacokineticsZhongXiYiJieHeXueBao/JChinIntegrMed,2006,4(2):147-151[1]1999(pharmacokinetics,PK)[2],,PK[3],,PK,[49],(ferulicacid,FA)PK,11.1Waters,:6007725996Millennium321.225g25g25g25g15g15g25g25g30g25g13,,,10,[10]:5g/kg,,630min(3200W)(1200W)60min,42400ml,0.825g/ml,,4,,,773-9203,(high-performanceliquidchromatography,HPLC)(99.3%)1.3,21,11,10;(40.26.9)2003320041161,28,33;(43.77.7);[11],20,2219;:,1.4,1.4.13d,(H2);,,150ml,2/d,10d1.4.2:KromasilC18(2504.6mm,5m,No.C18B011220);:()=4059.60.4,pH3.8;1.0ml/min;322nm;:-FA=(10.280.16)min,-=(7.330.13)min1.4.33.91mg,50ml,8412006342JournalofChineseIntegrativeMedicine,March2006,Vol.4,No.21(78.2g/ml),202(3.91g/ml)41.4.415h,892ml/kg151015306090120min81.5ml,,-201.4.51ml5ml,-10l(239.4ng),45s,3.5ml5min,10000r/min10min,5ml,57,,100l,10000r/min10min,50l1.4.61ml5ml,,7.8219.5539.1378.2597.75117.30156.42195.54ng,10l-,4560l,HPLC,8(Y)(X),r,1.4.73P97,PK,F22.1FAFA,;FA,10.5min;,321.3nm,FA121Figure1HPLCresultsofferulicacid(FA)indifferentserumsamplesA:Blankcontrolserumsamplefromhealthyperson;B:FAandp-hydroxybenzaldehyde-treatedserumsamplefromhealthyperson;C:JiaweiXiaoyaosanRecipe(JWXYSR)-treatedserumsamplefrompatient;a:FA;b:p-hydroxybenzaldehyde.2Figure2UltravioletspectrogramsofFAindifferentserumsamplesA:FAandp-hydroxybenzaldehyde-treatedserumsamplefromhealthyperson;B:JWXYSR-treatedserumsamplefrompatient.9412006342JournalofChineseIntegrativeMedicine,March2006,Vol.4,No.22.2FAFA7.82195.5ng/ml,Y=0.002418+0.013905X,r=0.99713,2.3FAFA5min,12.4FA,FAPK:,;PK:;PK:21FATable1SerumconcentrationsofFAatdifferenttimeinhealthypersonsandthepatientswithdifferentsyndromesaftertakingJWXYSR(xs,g/L)TimeaftertakingJWXYSR(min)SerumconcentrationHealthygroup(n=21)DSQgroup(n=22)SLQSDgroup(n=20)ESHgroup(n=19)5;104˜.3823.9126.776.6110¤.641.48116*.3858.2310;140˜.1230.3349.707.0322¤.814.86130*.4763.5915;152˜.9436.1162.396.9138¤.495.39109*.3441.6730;131˜.7627.2676.9510.3952¤.308.9386*.3924.1860;100˜.1922.8738.009.9833¤.763.2853*.2716.3690;95˜.7347.3927.656.5021¤.583.5529*.128.41120;87˜.2918.4716.573.2918¤.455.1717*.783.66DSQ:Syndromeofdeficiencyofspleenqi;SLQSD:Syndromeofstagnationofliverqiandspleendeficiency;ESH:Syndromeofexcessofstomachheat.2FATable2PharmacokineticsparametersofserumFAinhealthypersonsandthepatientswithdifferentsyndromesaftertakingJWXYSR(xs)PharmacokineticsparameterValueHealthygroup(n=21)DSQgroup(n=22)SLQSDgroup(n=20)ESHgroup(n=19)(min-1)0[.0930.0220¦.0410.014**0,.0580.021**0í.0950.610(min-1)0.00540.00310b.00270.0012**0è.00310.0102**0n.01100.0081**Ka(min-1)0„.380.120Ï.820.12**0U.190.01**0Û.710.02**t1/2(min)7„.631.4519ä.480.78**